Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011847 | 0.87 | MCHR1 (0.48) | HTTSMN1; SMN2KMT2ALMNA | |
| SCHEMBL12858371 | 0.85 | TSHR (0.46) | HTTALDH1A1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL1014420 | 0.84 | HTT (0.60) | HTTALDH1A1SMN1; SMN2KMT2APDE4B | |
| SCHEMBL1013959 | 0.83 | HTT (0.59) | HTTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1014491 | 0.80 | HIF1A (0.61) | SMN1; SMN2KMT2ALMNA | |
| SCHEMBL1014092 | 0.79 | ABL1 (0.50) | HTTALDH1A1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL1014530 | 0.77 | MAPT (0.51) | HTTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16884088 | 0.77 | HTT (0.76) | HTTALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4145433 | 0.76 | HTT (0.66) | HTTALDH1A1SMN1; SMN2PDE4BLMNA | |
| SCHEMBL25062318 | 0.76 | HTT (0.63) | HTTALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2272835-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034466-A1 | NOVEL FIVE-MEMBERED RING COMPOUND | CCL11, CCR1, CCR10 | HTT 4437/4885ALDH1A1 2564/4885SMN1; SMN2 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.